# C_2016227EN.01002401.xml

| 23.6.2016 | EN | Official Journal of the European Union | C 227/24 |
| --- | --- | --- | --- |

23.6.2016

EN

Official Journal of the European Union

C 227/24

---

Prior notification of a concentration

(Case M.7919 — Sanofi/Boehringer Ingelheim Consumer Healthcare Business)

(Text with EEA relevance)

(2016/C 227/07)

| 1. | On 15 June 2016, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Sanofi (Sanofi, France) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Boehringer Ingelheim’s consumer health care business (BI CHC, Germany), by way of purchase of shares and assets. |
| --- | --- |

1.

On 15 June 2016, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Sanofi (Sanofi, France) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Boehringer Ingelheim’s consumer health care business (BI CHC, Germany), by way of purchase of shares and assets.

1

| 2. | The business activities of the undertakings concerned are:
  —   for Sanofi: active in the research, development, manufacture and sale of healthcare products, including pharmaceuticals, human vaccines and animal health worldwide,
  —   for BI CHC: active worldwide in the research, development, manufacturing and marketing of human over-the-counter products — and by exception a few products under prescription — mainly in the area of gastro-intestinal treatments, cough and cold products, general pain and VMS (Vitamins, Minerals and Well-being Supplements). |
| --- | --- |

2.

The business activities of the undertakings concerned are:

—   for Sanofi: active in the research, development, manufacture and sale of healthcare products, including pharmaceuticals, human vaccines and animal health worldwide,

for Sanofi

—   for BI CHC: active worldwide in the research, development, manufacturing and marketing of human over-the-counter products — and by exception a few products under prescription — mainly in the area of gastro-intestinal treatments, cough and cold products, general pain and VMS (Vitamins, Minerals and Well-being Supplements).

for BI CHC

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.7919 — Sanofi/Boehringer Ingelheim Consumer Healthcare Business, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.7919 — Sanofi/Boehringer Ingelheim Consumer Healthcare Business, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

---